Background: Limited studies have compared the impact of different antiretroviral regimens on solublemarkers of inflammation with discordan tresults.Methods: In this prospective study, treatment naïve HIV-1-infected patients were included if they startedtheir current regimen with atazanavir/ritonavir(ATV/r)(N=73,Group1) or darunavir/ritonavir(DRV/r)(N=85,Group2) plus tenofovir/emtricitabine. The analysis of IL-6,MCP-1, sCD163, VCAM-1, ox-LDL,andadi-ponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation andthe second one year after initiation.Results: The results of our analysis show a difference in ox-LDL between the two groups with higher mean(SD) values in ATV/r based group 608.5±137.4 versus 519.1±119.6 in DRV/r group, after controlling forbaseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling.Conclusions: Our analysis provides further data examining the association between the modulation of vas-cular inflammatory and of activation markers with specific protease inhibitors-based treatments over oneyear of exposure to these drugs. The data show little evidence for an association, supporting the notion thatantiretroviral regimens has generally poor efficiency in downregulating these soluble markers.

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients

G. Nunnari
Membro del Collaboration Group
;
2018-01-01

Abstract

Background: Limited studies have compared the impact of different antiretroviral regimens on solublemarkers of inflammation with discordan tresults.Methods: In this prospective study, treatment naïve HIV-1-infected patients were included if they startedtheir current regimen with atazanavir/ritonavir(ATV/r)(N=73,Group1) or darunavir/ritonavir(DRV/r)(N=85,Group2) plus tenofovir/emtricitabine. The analysis of IL-6,MCP-1, sCD163, VCAM-1, ox-LDL,andadi-ponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation andthe second one year after initiation.Results: The results of our analysis show a difference in ox-LDL between the two groups with higher mean(SD) values in ATV/r based group 608.5±137.4 versus 519.1±119.6 in DRV/r group, after controlling forbaseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling.Conclusions: Our analysis provides further data examining the association between the modulation of vas-cular inflammatory and of activation markers with specific protease inhibitors-based treatments over oneyear of exposure to these drugs. The data show little evidence for an association, supporting the notion thatantiretroviral regimens has generally poor efficiency in downregulating these soluble markers.
2018
Vascular inflammation
activation markers
first-line antiretroviral therapy
atazanavir
darunavir
HIV
File in questo prodotto:
File Dimensione Formato  
Inflammatory effects of atazanavir.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 754.39 kB
Formato Adobe PDF
754.39 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/552222
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact